The information in this section is intended for visitors outside the United States.
Gilead Sciences to Release First Quarter 2018 Financial Results on Tuesday, May 1, 2018
Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress™ 2018
Gilead Sciences’ Norbert Bischofberger, PhD, to Step Down; John McHutchison, MD, Appointed Chief Scientific Officer and Andrew Cheng, MD, PhD, Appointed Chief Medical Officer
Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) From a Boosted Protease Inhibitor-Based Regimen or Boosted Elvitegravir-Containing Regimen
Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lamivudine
Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed Monkeys
Gilead Sciences Announces Senior Management Change
Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer
Gilead Sciences to Present at the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, February 21
U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Gilead Sciences Announces 10 Percent Increase in First Quarter 2018 Dividend
Gilead Sciences Announces Fourth Quarter and Full Year 2017 Financial Results
Jacqueline K. Barton, Ph.D., Joins Gilead Sciences’ Board of Directors
Gilead Sciences to Release Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 6, 2018
Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta™ (Axicabtagene Ciloleucel) and Pfizer’s Utomilumab in Large B-Cell Lymphoma
2015 Annual Review